RRC ID 62894
Author Sakurai Y, Ichinoe M, Yoshida K, Nakazato Y, Saito S, Satoh M, Nakada N, Sanoyama I, Umezawa A, Numata Y, Shi-Xu J, Ichihara M, Takahashi M, Murakumo Y.
Title Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors.
Journal Cancer Lett
Abstract REV7 is a multitasking protein involved in replication past DNA lesions, cell cycle regulation, and gene expression. REV7 is highly expressed in the adult testis and plays an essential role in primordial germ cell maintenance in mice. In this study, we analyzed whether REV7 can be a molecular target for the treatment of testicular germ cell tumors (TGCTs), in which acquired chemoresistance is a major cause of treatment failure. Strong expression of REV7 was detected in human TGCT tissues by immunohistochemistry. REV7 depletion in the TGCT cell lines suppressed cell proliferation and increased sensitivity to cisplatin and doxorubicin. cDNA microarray analysis revealed that REV7 depletion downregulated genes in the DNA repair gene set and upregulated genes in the apoptosis gene set. REV7 depletion-provoked chemosensitivity was associated with DNA double-strand break accumulation and apoptosis activation. In addition, inactivation of REV7 in cisplatin-resistant TGCT cells recovered chemosensitivity at almost equal levels as parental cells in vitro and in vivo. Our results indicate that inactivation of REV7 enhances chemosensitivity and overcomes chemoresistance in TGCT cells, suggesting REV7 as a potential therapeutic target in chemoresistant TGCTs.
Volume 489
Pages 100-110
Published 2020-10-1
DOI 10.1016/j.canlet.2020.06.001
PII S0304-3835(20)30303-7
PMID 32553781
MeSH Animals Drug Resistance, Neoplasm / physiology* Gene Expression Regulation, Neoplastic / physiology Heterografts Humans Mad2 Proteins / metabolism* Male Mice Mice, Inbred NOD Mice, SCID Neoplasms, Germ Cell and Embryonal / pathology* Testicular Neoplasms / pathology*
IF 7.36
Resource
Human and Animal Cells NEC8(RCB0489)